ORMP
ORAMED PHARMACEUTICALS INC.
NASDAQ · Healthcare · Biotechnology · US
$4.74
+1.50%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.66
From 52W high−11.24%
Volume775715.00
Market cap$197.17M
P/E (TTM)1.1x
P/S (TTM)—
Div yield5.27%
Key dataSep 18, 2026
Open
$4.66
From 52W high
−11.24%
Volume
775715.00
Market cap
$197.17M
ValuationView details →
P/E (Fwd)
5.9x
EV/EBITDA
1.0x
P/E (TTM)
1.1x
RSI (14)
46.3
MomentumView details →
1D Return
+1.50%
YTD Return
+62.46%
SummaryUpdated Jun 1, 2026
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage biotechnology company founded in 2002 and headquartered in New York. The company was originally incorporated as Integrated Security Technologies, Inc. before changing its name to Oramed Pharmaceuticals in April 2006 and going public in May 2007. Oramed specializes in developing oral drug delivery systems for medications that traditionally require injection, with a primary focus on creating the world's first commercially viable oral insulin capsule for diabetes treatment.
Similar companies
Latest newsMore news →
Lifeward Ltd. signed a securities purchase agreement to issue up to $11.16 million aggregate principal amount of senior secured convertible notes, with $5.58 million issued at closing on July 6, 2026, and the remainder subject to conditions.76d agoScilex loan was substantially repaid to Oramed Pharmaceuticals.87d ago